SEC 10-K / 10-Q · Updated Daily

AUPH

— Aurinia Pharmaceuticals Inc. Financials

Standardized 10-K and 10-Q line items with working capital, liquidity, solvency, profitability, efficiency, and cash-flow ratios — each chartable over any trailing window of filings, with every number confirmable against the original SEC document.

FinancialsOwnership

Latest Filing Snapshot — 10-Q for period ended 2026-06-30

MetricValueWhat it means
Current Ratio5.42Current assets ÷ current liabilities. Above 1 means short-term assets cover short-term obligations.
Debt-to-Equity0.29Total liabilities ÷ stockholders' equity — how much of the company is financed by debt vs. equity.
Net Margin44.96%Net income ÷ revenue.
Return on Equity6.08%Net income ÷ stockholders' equity.
Raw Line Items
Liquidity
Solvency & Leverage
Profitability
Efficiency
Cash Flow
Current Ratio
Not enough filings with this line item yet.

All Filings

FormFiscal PeriodPeriod EndFiledConfirm in Filing
10-Q— 2026-06-302026-08-06
10-Q— 2026-03-312026-05-07
10-K— 2025-12-312026-02-26
10-Q— 2025-09-302025-11-04
10-Q— 2025-06-302025-07-31
10-Q— 2025-03-312025-05-12
10-K— 2024-12-312025-02-27
10-Q— 2024-09-302024-11-07
10-Q— 2024-06-302024-08-01
10-Q— 2024-03-312024-05-02
10-K— 2023-12-312024-02-15
10-K/A— 2023-12-312024-04-29
10-Q— 2023-09-302023-11-02
10-Q— 2023-06-302023-08-03
10-Q— 2023-03-312023-05-04
10-K— 2022-12-312023-02-28
10-Q— 2022-09-302022-11-03
10-Q— 2022-06-302022-08-04
10-Q— 2022-03-312022-05-10
10-K— 2021-12-312022-02-28
10-Q— 2021-09-302021-11-03
10-Q— 2021-06-302021-08-05
10-Q— 2021-03-312021-05-06
10-K/A— 2020-12-312021-04-30
10-K— 2020-12-312021-02-24

Source: SEC EDGAR 10-K/10-Q XBRL data. For informational purposes only — not investment advice.